Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

Strip away the theatre — including the surreal moment when Israel’s Foreign Ministry summoned Spain’s chargé d’affaires over an Andalusian “Burning of Judas” effigy of Netanyahu stuffed with gunpowder ...

When McLaren announced earlier this month that it had prised GianPiero Lambiase away from Red Bull Racing, our immediate read ...

Health Secretary ⁠Robert ⁠F. Kennedy Jr. told a Senate ⁠hearing on Wednesday that he had nothing to do with the U.S. FDA's ...

After initially setting out plans to lay off dozens of workers in Massachusetts, Replimune Group is now increasing those ...

Replimune is axing 144 employees at its Woburn headquarters and 80 at its Framingham manufacturing site. The cuts follow the ...

After Replimune’s advanced melanoma drug was rejected for a second time, CEO Sushil Patel slammed the FDA for failing to ...

Replimune’s (REPL) investment thesis changed dramatically this week after the FDA rejected its lead cancer therapy, RP1, for ...

The Replimune Group, Inc. (NASDAQ: REPL) recently caught analysts’ attention as Jonathan Chang of Leerink Partners issued a “Market Perform” rating on April 13, 2026. This follow-up comes at a time ...

In a notable shift in investment sentiment, Replimune Group, Inc. (NASDAQ: REPL) received a “Hold” rating from Roger Song of Jefferies on April 13, 2026. With the stock currently priced at $4.76, the ...

Replimune received a second FDA complete response letter for RP1 in advanced melanoma, raising questions about the viability of its oncolytic immunotherapy program. Replimune Group received a complete ...

Replimune Group’s REPL share price is down 63% in the pre-market hours today after the company announced that the FDA has issued a second complete response letter (CRL) against its resubmitted ...